Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Filings indexed 994 across all filing types
Latest filing 2012-11-09 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2012
Regulatory Filings
2012-11-09 English
Annual Report 2012
Annual Report Classification · 100% confidence The document is a Form 20-F/A (Amendment No. 1) filed with the U.S. Securities and Exchange Commission (SEC) by RedHill Biopharma Ltd. The Form 20-F is an annual report filed by foreign private issuers, similar to the 10-K for U.S. companies. The document includes detailed sections such as identity of directors and senior management, offer statistics, key information, operating and financial review and prospects, financial statements, and exhibits. It contains comprehensive financial data, management discussion, and other disclosures typical of an annual report. The length of the document (15,000 characters) and the presence of detailed financial statements and management information confirm it is the full annual report filing rather than an announcement or certification. Therefore, the appropriate classification is Annual Report (10-K equivalent for foreign issuers).
2012-10-26 English
Regulatory Filings 2012
Regulatory Filings
2012-10-10 English
Regulatory Filings 2012
Regulatory Filings
2012-10-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.